Legend Biotech Corporation (LEGN), a biopharmaceutical company, on Tuesday announced positive preliminary data for LB2501 in treating B-cell non-Hodgkin lymphoma.
Following the release, shares rose over 42% on Tuesday.
Non-Hodgkin lymphoma (NHL) originates in lymphocytes, and B-cell Non-Hodgkin Lymphomas in particular arise from the abnormal growth and proliferation of B lymphocytes, which produce antibodies. BNHL accounts for 85% of all NHLs.
LB2501 is an investigational, CD19/CD20 dual-targeting in vivo CAR-T cell therapy that generates CAR-T cells in patients after a single intravenous infusion. The therapy thus eliminates the need for cell manufacturing and lymphodepletion.
An ongoing, open-label Phase 1 study is evaluating LB2501 in R/R B-NHL patients as a CAR-T cell approach to treating B-cell malignancies. Efficacy results from 12 patients treated across two dose levels (DL1 and DL2) were reported.
Patients on DL2 showed an objective response rate (ORR) of 100%, and a complete response rate (CRR) of 83.3%. A study of the drug's pharmacokinetics indicated a dose-dependent in vivo CAR-T expansion, and CAR-T cells were detected in peripheral blood for up to 116 days.
No dose-limiting toxicities or serious adverse events were reported in the trial. Infusion-related reactions occurred in 75% of patients, but all were recorded at or below Grade 2 severity.
LEGN closed Tuesday at $36.28, up 42.22%. In the overnight market, shares are trading at $35.25, down 2.84%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.